Product Images Gabapentin

This appears to be a formula in medical calculations for estimating creatinine clearance (CLCr) in adults, where CLCr is equal to the product of 0.85 for female patients and 72 times the serum creatinine level measured in mg/dL. The text is limited and does not provide any further context or explanation.*

The text is a chart displaying the mean pain score of individuals over a 4-week dose titration period and a subsequent 4-week fixed dose period. The chart compares the placebo group to those taking 3600 mg/day of gabapentin. There is no further information to provide a more detailed description.*

This appears to be a table or chart showing the mean pain score for a study involving four periods, including a placebo period and two periods of taking different doses of gabapentin. The baseline and the different weeks of the study are also noted. It is not clear what type of pain is being measured or any other details about the study.*

This is a chart showing the proportion of responders in controlled studies on PHN (postherpetic neuralgia), with percentages ranging from 0% to 100%. The values indicate the patient's level of pain reduction. The figure also shows the results of three controlled studies—GBP 3600, GBP 1800, and GBP 2400—with percentages ranging from 12% to 29%. The chart includes the symbol #p and some numeric expressions which may be references to statistical significance.*

This is a description of a medication package. The package was prepackaged by Bryant Ranck and is being compared to Neurontin 800mg Tablet by Alkem Laboratories Limited. The package contains 30 tablets with an expiration date of MM/YY and is identified by NDC 7133520371 and the code 03375301523487. The package also includes storage instructions to be kept at room temperature between 20°-25°C (68°-77°F) and a precautionary statement to keep all drugs out of reach of children.*